![Jake Simson](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Patrimonio netto: 43 200 $ in data 30/09/2026
Jake Simson is currently Director at Vivace Therapeutics, Inc., Outpace Bio, Inc., Convergent Therapeutics, Inc., AavantiBio, Inc., Cedilla Therapeutics, Inc., and Xenikos BV (Non-Executive Director).
Independent Director at Parabilis Medicines, Inc. (starting 2026), Janux Therapeutics, Inc. (since 2021), Tyra Biosciences, Inc. (since 2020), Bicara Therapeutics, Inc. (since 2023), and Septerna, Inc. (since 2023).
Director at DICE Molecules SV, Inc. (since 2021).
Partner at RA Capital Management LP and RA Capital Management LP (Private Equity) since 2020.
Former Independent Director at DICE Therapeutics, Inc. from 2020 to 2023.
Education includes a doctorate from The Johns Hopkins University conferred in 2013 and an undergraduate degree from Massachusetts Institute of Technology conferred in 2008.
| Società | Data | Numero di azioni | Valutazione | Data di valutazione |
|---|---|---|---|---|
| 11/06/2026 | 2.500 ( 0% ) | 43 200 $ | 30/09/2026 | |
| 09/06/2026 | 0 ( -.--% ) | - $ | 30/09/2026 | |
TYRA BIOSCIENCE, INC -.--% | 28/05/2026 | 0 ( -.--% ) | - $ | 30/09/2026 |
SEPTERNA, INC. -.--% | 26/06/2026 | 0 ( -.--% ) | - $ | 30/09/2026 |
| Società | Posizione | Inizio |
|---|---|---|
| TYRA BIOSCIENCES, INC. | Direttore/Membro del Consiglio | 01/01/2020 |
| JANUX THERAPEUTICS, INC. | Direttore/Membro del Consiglio | 01/03/2021 |
| BICARA THERAPEUTICS INC. | Direttore/Membro del Consiglio | 02/03/2023 |
| SEPTERNA, INC. | Direttore/Membro del Consiglio | 01/06/2023 |
| PARABILIS MEDICINES, INC. | Direttore/Membro del Consiglio | 01/01/2026 |
RA Capital Management LP
 RA Capital Management LP Investment ManagersFinance RA Capital is a multi-stage investment manager that focuses evidence-based investing in public and private healthcare and life science companies which develops drugs, medical devices, diagnostics, services, and research tools. The firm’s portfolio of private and public companies spans the globe and most therapeutic areas across all stages from discovery through commercialization. | Analyst-Equity | 01/12/2017 |
Outpace Bio, Inc.
 Outpace Bio, Inc. BiotechnologyHealth Technology Develops cell therapies | Direttore/Membro del Consiglio | - |
Convergent Therapeutics, Inc.
 Convergent Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops radiopharmaceutical therapies for prostate cancer | Direttore/Membro del Consiglio | - |
Cedilla Therapeutics, Inc.
 Cedilla Therapeutics, Inc. BiotechnologyHealth Technology Engages in discovering and exploiting unique insights into protein stability | Direttore/Membro del Consiglio | - |
| ░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░ ░░░ ░░░░░░░░░ | - |
| Società | Posizione | Fine |
|---|---|---|
| ░░░░ ░░░░ | ░░░░░░░░░░░░░░░░ ░░░ ░░░░░░░░░ | ░░░░░░░░░░ |
Attive
Inattive
Società nel listino
Aziende private
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
| Aziende private | 17 |
|---|---|
RA Capital Management LP
RA Capital Management LP Investment ManagersFinance RA Capital is a multi-stage investment manager that focuses evidence-based investing in public and private healthcare and life science companies which develops drugs, medical devices, diagnostics, services, and research tools. The firm’s portfolio of private and public companies spans the globe and most therapeutic areas across all stages from discovery through commercialization. | Finance |
Vivace Therapeutics, Inc.
 Vivace Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Discovers and develops novel cancer drug | Health Technology |
Massachusetts Institute of Technology
 Massachusetts Institute of Technology Finance/Rental/LeasingFinance Functions as a College/University | Finance |
The Johns Hopkins University
 The Johns Hopkins University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Xenikos BV
 Xenikos BV Medical SpecialtiesHealth Technology Develops medicines based on the action of antibodies | Health Technology |
DICE Therapeutics, Inc.
 DICE Therapeutics, Inc. BiotechnologyHealth Technology Develops oral immunology and other therapeutic products | Health Technology |
Parabilis Medicines
 Parabilis Medicines Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biopharmaceutical company that develops medicines for cancers and tumors | Health Technology |
Cedilla Therapeutics, Inc.
Cedilla Therapeutics, Inc. BiotechnologyHealth Technology Engages in discovering and exploiting unique insights into protein stability | Health Technology |
Tyra Biosciences, Inc.
 Tyra Biosciences, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biotechnology company that develops cancer treatment drug therapies | Health Technology |
RA Capital Management LP (Private Equity)
 RA Capital Management LP (Private Equity) Investment ManagersFinance RA Capital invests in both public and private companies located in the United States. The firm targets companies operating in the fields of healthcare and life sciences. It provides financing for pre-seed, seed stage, early stage and growth capital requirements . The firm acts as a lead and co-investor, makes follow-on investments and has a board seat requirement. | Finance |
DICE Molecules SV, Inc.
 DICE Molecules SV, Inc. Investment ManagersFinance Functions as an alternative investment manager | Finance |
Janux Therapeutics, Inc.
 Janux Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical-stage company that develops precision engineered immunotherapies | Health Technology |
Bicara Therapeutics, Inc.
 Bicara Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biopharmaceutical company that develops and sells therapeutics for tumors | Health Technology |
Aavantibio, Inc.
 Aavantibio, Inc. BiotechnologyHealth Technology Operates as biotechnology company that develops new gene therapies | Health Technology |
Outpace Bio, Inc.
Outpace Bio, Inc. BiotechnologyHealth Technology Develops cell therapies | Health Technology |
Convergent Therapeutics, Inc.
Convergent Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops radiopharmaceutical therapies for prostate cancer | Health Technology |
Septerna, Inc.
 Septerna, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biotechnology company that discovers and develops G protein-coupled receptor oral small molecule products for the treatment of hypoparathyroidism | Health Technology |
Seleziona la tua edizione
Tutte le informazioni finanziarie adattate in base al livello nazionale
